{"id":"NCT03338816","sponsor":"Alnylam Pharmaceuticals","briefTitle":"ENVISION: A Study to Evaluate the Efficacy and Safety of Givosiran (ALN-AS1) in Patients With Acute Hepatic Porphyrias (AHP)","officialTitle":"ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-11-16","primaryCompletion":"2019-01-31","completion":"2021-05-31","firstPosted":"2017-11-09","resultsPosted":"2020-02-11","lastUpdate":"2024-04-22"},"enrollment":94,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Hepatic Porphyria","Acute Intermittent Porphyria","Porphyria, Acute Intermittent","Acute Porphyria","Hereditary Coproporphyria (HCP)","Variegate Porphyria (VP)","ALA Dehydratase Deficient Porphyria (ADP)"],"interventions":[{"type":"DRUG","name":"Givosiran","otherNames":["ALN-AS1","GIVLAARI"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Givosiran/Givosiran","type":"EXPERIMENTAL"},{"label":"Placebo/Givosiran","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the effect of subcutaneous givosiran (ALN-AS1), compared to placebo, on the rate of porphyria attacks in patients with Acute Hepatic Porphyrias (AHP).","primaryOutcome":{"measure":"Annualized Rate of Porphyria Attacks in Participants With Acute Intermittent Porphyria (AIP)","timeFrame":"6 months","effectByArm":[{"arm":"Placebo","deltaMin":12.52,"sd":null},{"arm":"Givosiran 2.5 mg/kg","deltaMin":3.22,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":5},"locations":{"siteCount":36,"countries":["United States","Australia","Bulgaria","Canada","Denmark","Finland","France","Germany","Italy","Japan","Mexico","Netherlands","Poland","South Korea","Spain","Sweden","Taiwan","United Kingdom"]},"refs":{"pmids":["38044204","37479139","36028858","32521132"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":46},"commonTop":["Nausea","Injection site reaction","Fatigue","Nasopharyngitis","Headache"]}}